Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454986 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01454986 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT01454986, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG ALXN1007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454986
The ClinicalTrials.gov registry entry for NCT01454986 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01454986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454986 about?
NCT01454986 is a clinical study titled "Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects". The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
What is the current status of trial NCT01454986?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2011-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01454986?
The interventions under investigation include: Placebo (OTHER), ALXN1007 (DRUG).
Who is sponsoring clinical trial NCT01454986?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.